<DOC>
	<DOCNO>NCT01730456</DOCNO>
	<brief_summary>This multicenter , open-label , single arm , long-term extension study evaluate safety efficacy RoActemra/Actemra ( tocilizumab ) patient early moderate severe rheumatoid arthritis complete WA19926 core study . Patients receive RoActemra/Actemra 8 mg/kg intravenously every 4 week 104 week .</brief_summary>
	<brief_title>A Long-Term Extension Study RoActemra/Actemra ( Tocilizumab ) Patients With Early Moderate Severe Rheumatoid Arthritis Who Completed Study WA19926</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Patients complete last WA19926 core study visit ( Week 104 ) may benefit study drug treatment accord Investigator 's assessment No current recent adverse event laboratory find prevent use study drug dose RoActemra/Actemra 8 mg/kg baseline visit Receiving treatment outpatient basis Females childbearing potential must agree use least one adequate method contraception , include method failure rate &lt; 1 % per year , treatment period Pregnant lactate woman Patients prematurely withdrawn WA19926 core study reason Treatment investigational agent celldepleting therapy since last administration study drug WA19926 core study Immunization live/attenuated vaccine since last administration study drug WA19926 core study Diagnosis since last WA19926 visit ( Week 104 ) rheumatic autoimmune disease rheumatoid arthritis Diagnosis since last WA19926 visit ( Week 104 ) inflammatory joint disease rheumatoid arthritis Inadequate liver , hematologic renal function History severe allergic anaphylactic reaction humanize murine monoclonal antibody Known active history recurrent infection Evidence active malignant disease , malignancy within previous 10 year ( except basal cell carcinoma skin excise cure ) , breast cancer diagnose within previous 20 year Uncontrolled disease state , asthma inflammatory bowel disease , flare commonly treated oral parenteral corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>